The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacodynamic separation (PDS) of gemcitabine (Gem) and the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (Pts) with advanced pancreatic cancer: Phase II results.
Thomas John Semrad
Consultant or Advisory Role - Amgen; Genomic Health
Research Funding - Millennium; Novartis
Other Remuneration - Novartis (Speakers Bureau)
Heinz-Josef Lenz
Honoraria - Genentech/Roche
Research Funding - Genentech/Roche
I-Yeh Gong
No relevant relationships to disclose
Michael S. Tanaka
No relevant relationships to disclose
Courtney Eddings
No relevant relationships to disclose
Nichole Mahaffey
No relevant relationships to disclose
Philip C. Mack
No relevant relationships to disclose
Laurel Beckett
No relevant relationships to disclose
Primo Lara
Consultant or Advisory Role - Agennix; Genentech; Immunogen; Medivation; Pfizer; Teva
Honoraria - Elsevier
Research Funding - Genentech/Roche; GlaxoSmithKline; Janssen Oncology; Millennium; NCI